tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Acrux Transitions to Commercial Focus with New Leadership and Product Launches

Story Highlights
  • Acrux has launched three new generic topical products in the USA, boosting revenue growth.
  • New CEO John Warmbrunn leads Acrux’s shift from R&D to a commercial product portfolio.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Acrux Transitions to Commercial Focus with New Leadership and Product Launches

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Acrux ( (AU:ACR) ) has issued an update.

Acrux has announced the commencement of John Warmbrunn as the new CEO and Managing Director, succeeding Michael Kotsanis. The company has launched three new generic topical products in the USA, including Dapsone 7.5% Gel, which is contributing to accelerated revenue growth. The company received short-term RDTI funding from Radium Capital, supporting its transition from a research-focused entity to a commercialized product portfolio. The recent product launches, including Nitroglycerin 0.4% Ointment, have shown promising market traction, and Acrux aims to leverage its FDA-compliant product development capabilities to expand its market presence.

More about Acrux

Acrux Limited is a specialty topical pharmaceuticals development company based in Melbourne, Australia. The company focuses on developing and commercializing topical generic products, with a market focus on the United States and potential international expansion.

Average Trading Volume: 350,843

Technical Sentiment Signal: Sell

Current Market Cap: A$7.37M

See more insights into ACR stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1